CA3226034A1 - Pudexacianinium for nirf imaging - Google Patents

Pudexacianinium for nirf imaging Download PDF

Info

Publication number
CA3226034A1
CA3226034A1 CA3226034A CA3226034A CA3226034A1 CA 3226034 A1 CA3226034 A1 CA 3226034A1 CA 3226034 A CA3226034 A CA 3226034A CA 3226034 A CA3226034 A CA 3226034A CA 3226034 A1 CA3226034 A1 CA 3226034A1
Authority
CA
Canada
Prior art keywords
pudexacianinium
free form
urine
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3226034A
Other languages
English (en)
French (fr)
Inventor
Masako Saito
Komatsu KANJI
Shin TAKUSAGAWA
Leticia Delgado-Herrera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CA3226034A1 publication Critical patent/CA3226034A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3226034A 2021-07-28 2022-07-27 Pudexacianinium for nirf imaging Pending CA3226034A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163226534P 2021-07-28 2021-07-28
US63/226,534 2021-07-28
PCT/IB2022/056957 WO2023007404A1 (en) 2021-07-28 2022-07-27 Pudexacianinium for nirf imaging

Publications (1)

Publication Number Publication Date
CA3226034A1 true CA3226034A1 (en) 2023-02-02

Family

ID=82898903

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3226034A Pending CA3226034A1 (en) 2021-07-28 2022-07-27 Pudexacianinium for nirf imaging

Country Status (9)

Country Link
US (1) US20240342316A1 (https=)
EP (1) EP4376896A1 (https=)
JP (1) JP2024527715A (https=)
KR (1) KR20240041952A (https=)
CN (1) CN117715661A (https=)
AU (1) AU2022321011A1 (https=)
CA (1) CA3226034A1 (https=)
MX (1) MX2024001242A (https=)
WO (1) WO2023007404A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4605020A1 (en) * 2022-10-21 2025-08-27 Astellas Pharma, Inc. Composition for near infrared lymphatic imaging and uses and dosages therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041616T2 (hu) 2010-01-28 2019-05-28 National Univ Corporation Mie Univ Indocianin vegyület, szintézisének eljárása, tisztítási eljárása, indocianin vegyületet alkalmazó diagnosztikai készítmény, és készülék in vivo kinetika mérésére és készülék keringés megjelenítésére a diagnosztikai készítmény alkalmazásával

Also Published As

Publication number Publication date
US20240342316A1 (en) 2024-10-17
KR20240041952A (ko) 2024-04-01
CN117715661A (zh) 2024-03-15
WO2023007404A1 (en) 2023-02-02
MX2024001242A (es) 2024-02-13
AU2022321011A1 (en) 2024-01-25
EP4376896A1 (en) 2024-06-05
JP2024527715A (ja) 2024-07-26

Similar Documents

Publication Publication Date Title
Garbern et al. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium
Li et al. Mesencephalic astrocyte‐derived neurotrophic factor affords neuroprotection to early brain injury induced by subarachnoid hemorrhage via activating Akt‐dependent prosurvival pathway and defending blood‐brain barrier integrity
CN110267644B (zh) 用于治疗腺样囊性癌的苯磺酰胺衍生物的医药组合物
Murase et al. Randomized, double‐blind, controlled study to evaluate safety and pharmacokinetics of single ascending doses of ASP5354, an investigational imaging product, in healthy adult volunteers
BR112012017435A2 (pt) processo para a preparação de composições farmacêuticas para a liberação sustentada de análogos de somatostatina
US20240342316A1 (en) A pharmaceutical composition for imaging
BR112013014642A2 (pt) produto farmacêutico, kit, uso, produtos, métodos e usos inovadores
JP5211073B2 (ja) 子宮内膜症の治療用の薬剤
TW201121992A (en) Suppression of cancer metastasis
US20250161527A1 (en) Pharmaceutical compositions for hemostasis and wound healing in gastrointestinal tract
CN100379455C (zh) 预防或治疗子宫内膜异位症的药物
Trim et al. Horses with colic
WO2003074108A2 (en) Compositions for generating submucosal fluid cushions
HK40104552A (zh) 用於nirf成像的普地沙铵
JP7618235B2 (ja) ｐ－ボロノフェニルアラニンを含有する注射液剤の析出防止方法
Yang et al. Establishment of a novel rat model of different degrees of portal vein stenosis following 70% partial hepatectomy
CN117257803A (zh) 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用
TWI426923B (zh) 在以多層電腦斷層攝影進行之冠狀動脈攝影方法中依伐布雷定（ｉｖａｂｒａｄｉｎｅ）作為診斷劑之用途
JP7391400B2 (ja) 線溶系亢進薬、及びその用途
JP6706632B2 (ja) 半月板変性治療用組成物
CN103948617A (zh) 一种治疗和预防腹部手术后粘连的药物组合物
WO2022199551A1 (en) Dc009 for treating acute ischemic stroke
CN121534039A (zh) 一种含巴西苏木素的药物组合物及其制备方法和应用
CN116492447A (zh) Foxm1在制备治疗缺血性心脏病药物中的应用
WO2024023295A1 (en) Imatinib formulation for parenteral administration

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250526

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250526